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ABSTRACT
Resistance to antimicrobials is a significant and growing problem, limiting treatment options, especially
for serious Gram-positive infections. Ceftobiprole is a novel broad-spectrum cephalosporin that is active
in vitro against streptococci and staphylococci, including penicillin-resistant strains of pneumococci and
methicillin-resistant Staphylococcus aureus (MRSA). It maintains the activity of extended-spectrum
cephalosporins against Gram-negative bacteria, including Enterobacteriaceae. The in-vivo activity of
ceftobiprole has been demonstrated in mouse sepsis and subcutaneous abscess models of infection. Its
activity also has been examined in several discriminative models of infection that mimic specific
diseases in humans and permit testing of antimicrobial activity under a variety of defined
pharmacokinetic conditions. These include experimental pneumonia in mice, a tissue cage model of
foreign body infection in rats, and endocarditis models in rats and rabbits. In these models, ceftobiprole
exhibits activity equivalent or superior to that of comparators against MRSA, including vancomycin-
intermediate strains. These models also confirm the in-vivo activity of ceftobiprole against Gram-
negative bacteria that are susceptible in vitro. The results from animal models support the evaluation of
the clinical efficacy of ceftobiprole in humans and also predict clinical efficacy in the empirical treatment
of severe infections. The broad spectrum of activity may allow ceftobiprole to be used as monotherapy
for serious hospital-acquired infections where combination therapy would otherwise be required.
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INTRODUCTION
Since the mid-1970s, resistance to antimicrobials
has become a significant and escalating problem,
limiting treatment options for serious Gram-
positive infections in particular. The emphasis
placed on controlling Gram-negative infections
over recent decades may have unintentionally
contributed to the emergence of Gram-positive
bacteria as clinically significant nosocomial path-
ogens. Thus, hospitals increasingly have to deal
with infections caused by multidrug-resistant
organisms, particularly methicillin-resistant sta-
phylococci, penicillin- and erythromycin-resist-
ant pneumococci, and vancomycin-resistant
enterococci [1,2]. Data from the US National
Nosocomial Infections Surveillance System indi-
cate that the percentage of Staphylococcus aureus
isolates in hospitals that are resistant to methi-
cillin, oxacillin or nafcillin (collectively referred
to as MRSA) increased from 2% in 1975 to 29%
in 1991 and further to 46% by 2004 [3,4]. In 2004,
60% of Staph. aureus isolates from intensive care
unit patients were resistant to these agents, an
increase of 11% compared with the period from
1998 to 2002 [3]. If this trend continues, nosoco-
mial MRSA rates in the USA could exceed 70%
by the end of the decade. Although MRSA rates
vary between countries, similar increases are
evident worldwide and, furthermore, most
strains are also resistant to other classes of
antibiotic [5–7]. The use of vancomycin, previ-
ously an effective antibiotic against MRSA, has
led to the development of isolates with reduced
susceptibility [8,9]. Cases of vancomycin-resist-
ant Staph. aureus infections have been reported in
the medical literature and are of particular
concern [8,9]. Against such a background, there
is a need for new antimicrobial agents that are
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effective against not only MRSA but also other
antibiotic-resistant organisms.
Several new agents with Gram-positive activ-
ity, such as dalbavancin, daptomycin, linezolid,
quinupristin–dalfopristin, and tigecycline, have
or soon will reach the clinic [2]. Some, such as
tigecycline and linezolid, however, are bacterio-
static rather than bactericidal [2,10,11]. Bacteri-
cidal activity is important for therapeutic efficacy
in certain infections, such as endocarditis, men-
ingitis, and infections in neutropenic patients [12],
and bactericidal agents are often preferred in the
treatment of serious infections in hospitalised
patients [2]. Furthermore, none of the new agents
listed above, apart from tigecycline, has a broad
spectrum of activity including both Gram-positive
and Gram-negative pathogens, frequently restrict-
ing their use to combination therapy [13,14].
Ceftobiprole is a novel broad-spectrum,
b-lactamase-stable parenteral cephalosporin with
a strong affinity for the penicillin-binding pro-
teins PBP2a and PBP2x responsible for resistance
in staphylococci and pneumococci, respectively.
Ceftobiprole also can bind to relevant penicillin-
binding proteins of resistant Gram-positive and
Gram-negative bacteria and has a low ability to
select for resistance [15,16]. On the basis of
antimicrobial activity shown in animal models
of infection, ceftobiprole is undergoing further
clinical development.
ANIMAL MODELS OF INFECTION IN
THE EVALUATION OF
CEFTOBIPROLE
Several animal models have been used in the
evaluation of ceftobiprole, including mouse sep-
sis, abscess and pneumonia models, rat endocar-
ditis and tissue cage models, and a rabbit
endocarditis model (Table 1).
Screening models
The activity of ceftobiprole against a range of
Gram-positive and Gram-negative organisms has
been investigated in a mouse experimental septi-
caemia model, using comparators such as ceftri-
axone, vancomycin, and benzylpenicillin [15]. In
this model, MIC values measured in vitro corre-
lated well with in-vivo efficacy, as assessed by the
50% effective dose (ED50) (the dose required for
survival of 50% of the animals on the fourth day
after infection). Ceftobiprole showed high in-vivo
activity in infections caused by strains with MIC
values £ 2 mg ⁄L (Table 2). These included meth-
icillin-susceptible Staph. aureus, MRSA, Streptococ-
cus pyogenes, Streptococcus pneumoniae, Escherichia
coli, Klebsiella pneumoniae, Citrobacter freundii, Ser-
ratia marcescens, and Proteus mirabilis. Ceftobiprole
was superior to ceftriaxone and vancomycin
against methicillin-susceptible Staph. aureus, with
an ED50 below 0.2 mg ⁄kg. The MIC90 obtained for
ceftobiprole against 77 isolates of MRSA was
£ 4 mg ⁄L, as compared to > 64, > 32, > 32, > 8 and
> 2 mg ⁄L, respectively, for cefotaxime, cefepime,
meropenem, ciprofloxacin, and vancomycin.
Ceftobiprole exhibited good in-vivo activity
against group A streptococci and penicillin-
Table 1. Animal models of infection in the evaluation of
ceftobiprole
Animal Model Infective agent
Mouse Sepsis Gram-positive and Gram-negative
Mouse Abscess MRSA, VISA
Mouse Pneumonia Haemophilus influenzae, Enterobacter cloacae,
Klebsiella pneumoniae
Rat Endocarditis MRSA
Rat Tissue cage MRSA
Rabbit Endocarditis MRSA, VISA
MRSA, methicillin-resistant Staphylococcus aureus; VISA, vancomycin-intermediate
Staph. aureus.
Table 2. Activity of ceftobiprole and comparators in
experimental mouse sepsis
Organism Agent MIC (mg ⁄L) ED50 (mg ⁄kg)
Gram-positives
MSSA Ceftobiprole 0.25 < 0.2
Ceftriaxone 4 0.89
Vancomycin 1 0.73
MRSA Ceftobiprole 2 2.4
Vancomycin 2 6.7
GAS Ceftobiprole £ 0.06 < 0.2
Ceftriaxone £ 0.06 < 0.2
PSSP Ceftobiprole £ 0.06 < 0.2
Benzylpenicillin £ 0.06 < 0.4
PRSPa Ceftobiprole 1 1.0
Ceftriaxone 4 8.8
Gram-negatives
Escherichia coli Ceftobiprole £ 0.06 < 0.2
Ceftriaxone £ 0.06 < 0.2
Enterobacter cloacae Ceftobiprole 4 3.8
Cefepime 2 1.1
Meropenem £ 0.06 0.22
Serratia marcescens Ceftobiprole 0.25 0.68
Meropenem £ 0.06 0.45
Proteus vulgaris Ceftobiprole > 32 > 12
Meropenem £ 0.06 < 0.4
Pseudomonas aeruginosa Ceftobiprole 8 4.0
Cefepime 4 1.0
Meropenem 2 < 0.4
Adapted from Hebeisen et al. [15] with permission.
aStrain 23 F-CTR.
ED50, dose at which 50% of animals survived, assessed on the fourth day after
infection; MSSA, methicillin-susceptible Staphylococcus aureus; MRSA, methicillin-
resistant Staph. aureus; GAS, group A streptococci (Streptococcus pyogenes); PSSP,
penicillin-susceptible Streptococcus pneumoniae; PRSP, penicillin-resistant Strep.
pneumoniae.
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susceptible Strep. pneumoniae, as expected since
b-lactams are effective against these organisms,
but was also active against penicillin-resistant
streptococci, including a strain (23 F-CTR) with a
reduced in-vitro (MIC = 4 and 8 mg ⁄L for ceftri-
axone and cefotaxime, respectively, vs. 1 mg ⁄L
for ceftobiprole) and in-vivo activity (ED50 = 8.8
and > 12 mg ⁄ kg, respectively, vs. 1 mg ⁄kg sub-
cutaneously) susceptibility to extended-spectrum
cephalosporins. Results with Enterobacteriaceae
were also encouraging. Low ED50 values with
ceftobiprole were comparable to those obtained
with cefepime and superior to those with ceftri-
axone against Enterobacter cloacae and C. freundii
strains that produce class C chromosomal b-lacta-
mase. However, the activity of all b-lactamases
against Gram-negative pathogens depends on
the class and amount of b-lactamase produced.
Meropenem was superior to both cefepime and
ceftobiprole in this model because of its stability
towards b-lactamases produced by selected bac-
teria. Ceftobiprole was inactive against P. vulgaris
as a result of hydrolysis by the broad-spectrum
K1 b-lactamase of this organism. Ceftobiprole,
like cefepime and ceftriaxone, is hydrolysed by
extended-spectrum b-lactamases and inactive
against strains producing these enzymes.
The bactericidal properties of ceftobiprole have
been demonstrated in a mouse model in which
subcutaneous abscesses were induced using two
MRSA strains, a vancomycin-intermediate (VISA)
strain (Mu50) and a vancomycin-susceptible
strain (I-6) [15]. Ceftobiprole (10 mg ⁄ kg) was
bactericidal compared with vancomycin
(10 mg ⁄ kg) and linezolid (20 mg ⁄kg) against the
vancomycin-susceptible strain, achieving a med-
ian decrease in log10 CFU in comparison with
untreated controls of 5.12 (n = 21) vs. decreases in
comparison with untreated controls (n = 21) of
3.42 with vancomycin (n = 21) and 0.80 with
linezolid (n = 5). The bactericidal properties of
ceftobiprole against MRSA have also been dem-
onstrated in an endocarditis rat model, where it
was more effective than vancomycin and amoxy-
cillin–clavulanic acid [17]. Ceftobiprole was also
highly effective against the VISA strain, com-
pletely eliminating the pathogen from most ani-
mals, whereas vancomycin and linezolid effected
only a minor reduction (0.13 and 0.64 log10 units
in comparison with untreated controls, respect-
ively; n = 5 for all four groups) [17]. This outcome
was in accordance with the in-vitro finding that
the MIC of ceftobiprole for the VISA strain was
the same as that for the vancomycin-susceptible
strain of Staph. aureus [15]. Linezolid, a bacterio-
static rather than bactericidal agent [10,12], was
unable to eliminate the infecting organisms in this
model.
Discriminative models
Although it is impossible to exactly duplicate a
human infection and the process for drug absorp-
tion and clearance in an animal model, discrimi-
native animal models attempt to do so by
incorporating pharmacokinetic parameters. The
critical pharmacokinetic factor with b-lactamase
antibiotics is time rather than concentration, such
that the duration for which the MIC value for a
particular organism is exceeded is a better predic-
tor of efficacy than peak concentration. A 750-mg
dose of ceftobiprole administered as an intraven-
ous infusion over 30 min in single- and multiple-
dose studies resulted in a mean peak plasma
concentration of 0.60–0.61 mg ⁄L per hour, a mean
AUC value of 135–165 mg ⁄L per hour, and amean
half-life of 3–4 h. The value of T > MIC at which
100% of MRSA isolates were inhibited (< 4 mg ⁄L)
was approximately 7–9 h (Table 3) [18,19].
In mice, the half-life of ceftobiprole is shorter
than in humans, such that in themouse pneumonia
model in which ceftobiprole has been evaluated
[RouseM,Anguı´ta-AlonsoP,HanM, Steckelberg J,
Patel R. Activity of BAL5788 in Haemophilus
influenzae, Enterobacter cloacae or Klebsiella pneumo-
niae experimental murine pneumonia. 44th
Table 3. Pharmacokinetic parame-
ters of ceftobiprole in humans and
discriminative animal models of
infection
Dose (mg) Peak (lg ⁄mL)
AUC
(lg h ⁄mL) T1 ⁄ 2 (h)
T > 4
(lg ⁄mL) (h)
Human [18,19]
(single dose)
750 60–61 135–165 3–4 7–9
Mouse pneumonia [20] 50 four times daily 25 22.5 0.25–0.5 1.5
Rat tissue cage [21] 150 twice daily 16–25 120 3 9
Rat endocarditis [17] Constant
infusion
5.5–6.8
11.9–14.5
144
290
NA ¥
24.2–27.3 600
Rabbit endocarditis [22] 19 three times daily 29 NA 1 3–4
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ICAAC 2004, abstract B-1177] the AUC value is
lower than in humans and the 4 mg ⁄L MIC
concentration is exceeded for only 1.5 h (Table 3).
This means that the experimental conditions are
biased against ceftobiprole. In other models
[17,21,22], the concentrations and time above MIC
aremore comparablewithwhatwould be achieved
in humans, but towards the lower range (Table 3).
In none of the models, therefore, are the pharma-
cokinetic conditions preferential to ceftobiprole.
In the mouse pneumonia model, ceftobiprole
(50 mg ⁄kg four times daily) administered 24 h
after infection and continued for 48 h showed in-
vivo activity against Haemophilus influenzae,
Ent. cloacae, and extended-spectrum b-lactamase-
negative K. pneumoniae (Table 4) (Rouse M,
Anguita-Alonso P, HeinMH, Steckelberg JM, Patel
R. Activity of BAL5788 in Haemophilus influenzae,
Enterobacter cloacae or Klebsiella pneumoniae Experi-
mental Murine Pneumonia. 44th ICAAC 2004,
abstract B-1177). Ceftobiprole, ceftriaxone
50 mg ⁄ kg twice daily and cefepime 50 mg ⁄kg
four times daily were effective compared with
untreated animals (p < 0.05), and there were no
significant differences among the three treatments.
All three antibiotics produced a significant reduc-
tion in viable counts for all isolates except exten-
ded-spectrum b-lactamase-positive K. pneumoniae,
for which no effect was observed for any agent.
Foreign body infections, the majority of which
are caused by staphylococci, are extremely resist-
ant to antibiotics, even those with in-vitro activity,
and contribute significantly to the problem of
nosocomial infections [23,24]. The tissue cage
model is a foreign body infection model in which
MRSA is injected into preimplanted Teflon tissue
cages [25]. In the evaluation of ceftobiprole using
this model, rats were treated 2 weeks after bac-
terial infection with ceftobiprole or vancomycin
for 7 days [21]. The dose of ceftobiprole, equival-
ent to 150 mg ⁄kg twice daily, was chosen such
that the time for which plasma concentration was
> 4 lg ⁄mL was similar to that obtained in humans
(Table 3). Ceftobiprole and vancomycin 50 mg ⁄ kg
twice daily were equally efficacious in this model,
achieving mean decreases in log10 CFU ⁄mL
(± SEM) of 0.7 ± 0.3 (n = 29) and 0.9 ± 0.2
(n = 28), respectively, compared with an increase
of 0.2 ± 0.2 (n = 30) in untreated rats. However,
the reductions achieved are relatively low com-
pared with the 2–6 log10 changes seen in other
animal infection models, such as the mouse
pneumonia model described above (Table 4),
reflecting the difficulty of treating foreign body
infections.
Ceftobiprole has shown superiority to vanco-
mycin in a model in which endocarditis is
induced in rats via aortic catheterisation [17].
Two MRSA strains were investigated, COL Bla+
and P8-Hom, both homogeneously methicillin-
resistant, b-lactamase-producing strains. Rats
were given a constant infusion of ceftobiprole to
achieve a steady-state concentration of 5, 10 or
20 mg ⁄L (Table 3) or 1 g of vancomycin every
12 h at a flow rate designed to mimic intermittent
intravenous treatment in humans. Treatment
began 12 h after bacterial challenge and contin-
ued for 3 days. Ceftobiprole was effective against
both strains of MRSA, sterilising > 90% of cardiac
vegetations. Against the COL Bla+ strain, all three
infusion regimens were effective compared with
untreated animals (p < 0.05), with the two higher
steady-state levels (10 and 20 mg ⁄L) rendering
significantly more animals culture-negative than
vancomycin treatment (p < 0.05). Against the P8-
Hom strain, where only the ceftobiprole 5 mg ⁄L
level was investigated, 100% of animals were
rendered sterile, a significantly better result than
that achieved with vancomycin (p < 0.05).
Ceftobiprole has also demonstrated in-vivo
activity in a rabbit model of aortic valve endocar-
ditis using MRSA (strain 76) and VISA (New
Jersey strain HIP5836). Ceftobiprole 19 mg ⁄ kg
three times daily for 4 days significantly
Table 4. Activity of cephalosporins
in a mouse pneumonia model
[Rouse M, Anguı´ta-Alonso P, Han
M, Steckelberg J, Patel R. Activity of
BAL5788 in Haemophilus influenzae,
Enterobacter cloacae or Klebsiella pneu-
moniae experimental murine pneu-
monia. 44th ICAAC 2004, abstract
B-1177]
Haemophilus
influenzae
Enterobacter
cloacae
ESBL– Klebsiella
pneumoniae
ESBL+ Klebsiella
pneumoniae
Sterile Log10 CFU Sterile Log10 CFU Sterile Log10 CFU Sterile Log10 CFU
Untreated 0 ⁄ 15 4.9 0 ⁄ 16 6.0 0 ⁄ 16 6.8 0 ⁄ 16 6.1
Ceftobiprolea 9 ⁄ 15 < 2.5b 4 ⁄ 16 3.6 2 ⁄ 15 < 2.5b 0 ⁄ 16 6.4
Ceftriaxone 11 ⁄ 15 < 2.5b 5 ⁄ 18 3.6 1 ⁄ 15 < 2.5b 0 ⁄ 16 6.2
Cefepime 15 ⁄ 15 < 2.5b 4 ⁄ 15 3.4 2 ⁄ 14 2.7 0 ⁄ 16 6.0
ESBL, extended-spectrum b-lactamase.
aCeftobiprole (50 mg ⁄ kg twice daily), ceftriaxone (50 mg ⁄ kg twice daily) or cefepime (50 mg ⁄ kg four times daily)
were commenced 24 h after infection and continued for 48 h.
bLimit of detection, 2.5 log10 CFU ⁄ g lung.
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decreased vegetations of both strains in compar-
ison with controls (Fig. 1) [22]. Significant reduc-
tions in comparison with controls were evident in
the spleen and kidney, and at the site of infection
(Fig. 1). Vancomycin was effective only against
MRSA strain 76 in this model. The mortality rate
for animals infected with MRSA strain 76 approa-
ched 50% in both the ceftobiprole and vanco-
mycin groups, but this probably reflected the
overwhelming nature of the infection rather than
treatment failure. In animals infected with VISA,
mortality was significantly lower in the ceftobi-
prole group than in the vancomycin group (8% vs.
67%, p = 0.022). Given the absence of decrease of
bacterial burden in surviving animals treated with
vancomycin, the higher death rate is probably
attributable to treatment failure with vancomycin.
In the tissue cage rat model of foreign body
MRSA (MRGR3, isolated from catheter-related
sepsis) infection, MIC ⁄MBC values for ceftobi-
prole and vancomycin obtained in vitro were 1 ⁄ 4
and 1 ⁄ 2, respectively [21]. Treatment for 7 days
significantly reduced tissue cage counts of viable
MRGP3 by 0.68 ± 0.28 log10 CFU ⁄mL, which was
not significantly different from values obtained
for ceftobiprole-treated rats. No resistant colonies
were observed.
CONCLUSIONS
Ceftobiprole is an investigational novel cepha-
losporin that is active in vitro against streptococci
and staphylococci, including penicillin-resistant
strains of pneumococci and MRSA, while main-
taining the activity of extended-spectrum
cephalosporins against Gram-negative organisms.
The activity of ceftobiprole is based on inhibition
of penicillin-binding proteins, including those
responsible for resistance in MRSA, and stability
against hydrolysis by b-lactamases. In vivo,
screening models predict good activity for cefto-
biprole against Gram-positive and many Gram-
negative bacteria, including some important
Enterobacteriaceae. Under a variety of pharma-
cokinetic conditions, discriminative models of
infection have confirmed that ceftobiprole is
active against MRSA, including vancomycin-
intermediate strains. These findings in animal
models support the evaluation of ceftobiprole in
human infections. Furthermore, these results may
predict the clinical efficacy of ceftobiprole both as
empirical therapy while culture results are awai-
ted and as a definitive therapy for infections
caused by methicillin-resistant staphylococci. The
results of a phase II study in patients with
complicated skin and skin structure infections
were reported recently [25], and multicentre,
randomised, controlled phase III studies to deter-
mine the efficacy and safety of ceftobiprole have
been initiated. The broad spectrum of activity of
ceftobiprole may permit its use as monotherapy
in situations where a combination antibacterial
regimen might otherwise be required.
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